About us

The Byrne Lab aims to understand the underlying immunobiology regulating therapeutic sensitivity – or resistance – in pancreatic cancer. Our research focuses on bridging innate and adaptive immune responses to drive tumor rejection using preclinical models of cancer. These findings are then translated to the clinical setting, where we aim to identify biological correlates of response in patients.

Our approach leverages genetically engineered mouse models of spontaneous pancreatic cancer that recapitulate key features of human disease. We utilize several immune cell assays including flow cytometry, microscopy, cell culture, and adoptive cell transfers to interrogate the mechanisms regulating the immune response against the tumor and identify novel therapeutic targets for further investigation.

The Byrne Lab is part of the Cell, Developmental, and Cancer Biology Department and the Knight Cancer Institute, as well as the Brenden-Colson Center for Pancreatic Care, resulting in a community of basic and translational researchers for our lab to collaborate with and learn from. 

Lab Events

group of people sitting at table
Byrne Lab Outing for ice cream with our Summer 2022 interns
Four people in a group.
2022 CDCB Summer Interns presenting their data
Six people sitting at tables outside.
Byrne Lab celebrating Margaret's N.L. Tartar Trust Fellowship Award!
Eleven people on a beach.
A few Byrne Lab members survived the Hood to Coast Relay in 2022
Four people in front of a sign.
Byrne Lab 2022 end-of-year outing to OMSI After Dark